Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk.

ABSTRACT: Some health concerns are often not identified until late into clinical development of drugs, which can place participants and patients at significant risk. For example, the United States Food and Drug Administration (FDA) labeled the xanthine oxidase inhibitor febuxostat with a"boxed" warning regarding an increased risk of cardiovascular death, and this safety risk was only identified during Phase 3b clinical trials after its approval. Thus, better preclinical assessment of drug efficacy and safety are needed to accurately evaluate candidate drug risk earlier in discovery and development. This study explored whether an in vitro vascular model incorporating human vascular cells and hemodynamics could be used to differentiate the potential cardiovascular risk associated with molecules that h

SUBMITTER: Feaver RE 

PROVIDER: S-EPMC10490929 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature